COMUNICATO STAMPA SPONSORIZZATO – The World’s First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia

(Immediapress) – CorrectSequence Therapeutics’ CS-121 Completed Dosing of First Chylomicronemia Patient, Demonstrating Excellent Safety and Significant Efficacy SHANGHAI, Nov. 5, 2025 /PRNewswire/ — On November 6, 2025, Shanghai, China, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for the treatment of severe diseases, announced that the first patient in its Investigator-Initiated Trial (IIT) of the […] L'articolo COMUNICATO STAMPA SPONSORIZZATO – The World’s First Gene-Editing Therapy Targeting APOC3 for Hyperlipidemia proviene da La Ragione.

CONTINUA A LEGGERE